Sage Journals: Discover world-class research

Sort by:

Relevance

Select allExport selected citations

Sort by:

Relevance

Retricted access

Research article

First published 2011-02

Qualitative Spectral OCT/SLO Analysis of Drusen Change in Dry Age-Related Macular Degeneration Patients Treated with Copaxone

Gennady Landa, Richard B. Rosen, Amar Patel [...]

Journal of Ocular Pharmacology and Therapeutics

Retricted access

Research article

First published 1996-06

Management of relapsing/remitting multiple sclerosis with copolymer I (Copaxone)

Kenneth P Johnson

Multiple Sclerosis Journal

Retricted access

Research article

First published 2007-01

Human Mesenchymal Stem Cells Constitutively Express Chemokines and Chemokine Receptors That Can Be Upregulated by Cytokines,IFN-β,and Copaxone

Juliana Croitoru-Lamoury, Francois M.J. Lamoury, John J. Zaunders [...]

Journal of Interferon & Cytokine Research

Retricted access

Research article

First published 2012-1

Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate,Copaxone®,and TV-5010,Protiramer) in Rats and Monkeys

Yuval Ramot, Moti Rosenstock, Ety Klinger [...]

Toxicologic Pathology

Retricted access

Research article

First published 2004-1

Management of Glatiramer (Copaxone) Reactions: Experience with Desensitization

SR Inamdar, M Rensel, F Hsieh [...]

Journal of Investigative Medicine

Retricted access

Research article

First published 2008-07

Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®)

C Iarlori, D Gambi, A Lugaresi [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2016

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis

Michael D Ludwig, Anthony P Turel, Ian S Zagon [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2001-12

A prospective,open-label treatment trial to compare the effect of IFNβ-1a (Avonex®),IFNβ-1b (Betaseron®),and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy

Omar A Khan, Alexandros C Tselis, John A Kamholz [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2003-12

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

K P Johnson, B R Brooks, C C Ford [...]

Multiple Sclerosis Journal

Retricted access

Case report

First published 2019-2

In Re: Copaxone Consol. Cases United States Court of Appeals of the Federal Circuit,2018 906 F.3d 1013

Biotechnology Law Report

Search results